<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We identified HLA-DRB1*0901-binding <z:chebi fb="7" ids="16670">peptides</z:chebi> by affinity-based selection of a phage random <z:chebi fb="7" ids="16670">peptide</z:chebi> library using the biotinylated DR9 complex </plain></SENT>
<SENT sid="1" pm="."><plain>Analogue <z:chebi fb="7" ids="16670">peptides</z:chebi> with single amino acid residue substitutions of a DR9 binder revealed that two major anchors (WxxS, where x is any amino acid) play an essential role in binding to DR9 </plain></SENT>
<SENT sid="2" pm="."><plain>Determination of the binding affinity of synthetic <z:mp ids='MP_0002169'>wild-type</z:mp>-based analogue <z:chebi fb="7" ids="16670">peptides</z:chebi> showed that substituting W to F or L, and S to A, V, or F allow high affinity binding with DR9 </plain></SENT>
<SENT sid="3" pm="."><plain>Collectively, DR9-binding <z:chebi fb="7" ids="16670">peptide</z:chebi> motifs identified in this study are characteristic in that (a) only two anchors of the <z:chebi fb="0" ids="29318,29339">NH2</z:chebi>-terminal half of binding <z:chebi fb="7" ids="16670">peptides</z:chebi> play important roles in binding, and (b) small neutral hydrophilic Ser is allowed as the second anchor for high-affinity binding, unlike the other DR-binding motifs heretofore reported </plain></SENT>
<SENT sid="4" pm="."><plain>The implications of our results are discussed in light of the HLA-DR9-associated susceptibility to <z:hpo ids='HP_0003621'>juvenile-onset</z:hpo> <z:hpo ids='HP_0003473'>myasthenia</z:hpo> gravis and <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> with <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e>, in particular, T-cell responses to autoantigens </plain></SENT>
</text></document>